Organovo Holdings Company Profile (NYSE:ONVO)

Consensus Ratings for Organovo Holdings (NYSE:ONVO)(?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.

Ratings Breakdown:

No ratings tracked in the last 12 months.

Consensus Rating:

N/A (Score: NaN)

Consensus Price Target:

N/A

Analysts' Ratings History for Organovo Holdings (NYSE:ONVO)

Show:

No equities research coverage for this company has been tracked by Analyst Ratings Network

Earnings History for Organovo Holdings (NYSE:ONVO)No earnings announcements for this company have been tracked by Analyst Ratings Network

Dividend History for Organovo Holdings (NYSE:ONVO)No dividend announcements for this company have been tracked by Analyst Ratings Network

Insider Trading History for Organovo Holdings (NYSE:ONVO)No insider trades for this company have been tracked by Analyst Ratings Network

About Organovo Holdings

ORGANOVO HOLDINGS, INC., is a development-stage company. The Company is focused on developing and commercializing functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. We intend to introduce a paradigm shift in the approach to the generation of three-dimensional human tissues, by utilizingthe Company'sproprietary platform technology to create human tissue constructs in 3D that mimic native human tissue composition and architecture. The Company's NovoGen Bioprinters serve as important components of the company's tissue prototyping and manufacturing platform.

Subscribe

Subscribe to ARN Daily and get analysts' upgrades, downgrades and new coverage delivered directly to your email inbox daily using the form below:

Recent Ratings

Alacer Gold Corp (ASR) had its price target raised by analysts at Scotiabank from C$2.75 to C$3.25. They now have a "sector perform" rating on the stock. (3/31/2015)

Belo Sun Mining Corp (BSX) had its price target lowered by analysts at Scotiabank from C$0.70 to C$0.60. They now have a "sector perform" rating on the stock. (3/31/2015)

Gildan Activewear Inc (GIL) had its price target lowered by analysts at Scotiabank from C$82.00 to C$42.00. They now have an "outperform" rating on the stock. (3/31/2015)

WSP Global Inc (WSP) was downgraded by analysts at Raymond James from a "strong-buy" rating to an "outperform" rating. They now have a C$48.00 price target on the stock, up previously from C$46.00. (3/31/2015)